Qiagen developing, releasing assays for NeuMoDx system

2019 05 15 20 52 2340 Lab Pcr Tubes Dna 400

Qiagen on Thursday announced new additions to its NeuMoDx assay menu for organ transplant-associated viruses.

The assays, which permit the identification and quantification of the Epstein-Barr virus (EBV) and human herpesvirus 6 (HHV-6), have received CE-IVD certification for use in countries in the European Union and other countries that accept the CE Mark, Qiagen said.

The assay menu for transplant-associated viruses is used for viral load monitoring for the management of immunocompromised patients such as organ transplant patients, the firm said.

Its NeuMoDx three-step molecular diagnostics system extracts DNA from blood or urine samples to isolate target nucleic acids and then conduct reverse-transcription polymerase chain reaction (RT-PCR) tests. It is designed to automate workflow and is based on a microfluidic cartridge system, allowing the running of 12 reactions at once by hospital and clinical reference laboratories, Qiagen said.

The firm on Thursday also announced that it will launch a monkeypox research-use-only assay in 2022 for research and surveillance of the two current variants of the monkeypox virus, Clade I and Clade II.

Qiagen further intends to launch a new multiple-target assay that can differentiate between flu A and flu B, the two most common strains of influenza; respiratory syncytial virus (RSV); and SARS-CoV-2. The conditions are differentiated from one another in individuals suspected by a healthcare provider of respiratory viral infection. Qiagen said that the assay's dual target design will improve its robustness to lower the risk of future SARS-CoV-2 variants affecting its performance.

In September 2020, Qiagen acquired the remaining 80.1% of NeuMoDx Molecular for $248 million in cash.

In 2018, Qiagen paid $234 million to purchase a 19.9% stake in NeuMoDx along with the right to acquire the remaining stake.

Page 1 of 11
Next Page